| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Clovis Oncology Inc (NASDAQ: CLVS)
CLVS Technical Analysis
5
| As on 22nd Feb 2023 CLVS SHARE Price closed @ 0.09 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.52 & Strong Sell for SHORT-TERM with Stoploss of 4.35 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CLVSSHARE Price
| Open | 0.08 | Change | Price | % |
| High | 0.10 | 1 Day | 0.00 | 0.00 |
| Low | 0.08 | 1 Week | -0.02 | -18.18 |
| Close | 0.09 | 1 Month | 0.02 | 28.57 |
| Volume | 361782 | 1 Year | -4.55 | -98.06 |
| 52 Week High 4.87 | 52 Week Low 0.00 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CLVS Daily Charts |
CLVS Intraday Charts |
Whats New @ Bazaartrend |
CLVS Free Analysis |
|
|
CLVS Important Levels Intraday
| RESISTANCE | 0.13 |
| RESISTANCE | 0.12 |
| RESISTANCE | 0.11 |
| RESISTANCE | 0.10 |
| SUPPORT | 0.08 |
| SUPPORT | 0.07 |
| SUPPORT | 0.06 |
| SUPPORT | 0.05 |
CLVS Forecast April 2024
| 4th UP Forecast | 1.61 |
| 3rd UP Forecast | 1.12 |
| 2nd UP Forecast | 0.82 |
| 1st UP Forecast | 0.52 |
| 1st DOWN Forecast | -0.34 |
| 2nd DOWN Forecast | -0.64 |
| 3rd DOWN Forecast | -0.94 |
| 4th DOWN Forecast | -1.43 |
CLVS Weekly Forecast
| 4th UP Forecast | 1.38 |
| 3rd UP Forecast | 0.97 |
| 2nd UP Forecast | 0.71 |
| 1st UP Forecast | 0.46 |
| 1st DOWN Forecast | -0.28 |
| 2nd DOWN Forecast | -0.53 |
| 3rd DOWN Forecast | -0.79 |
| 4th DOWN Forecast | -1.20 |
CLVS Forecast2024
| 4th UP Forecast | 9.55 |
| 3rd UP Forecast | 6.52 |
| 2nd UP Forecast | 4.64 |
| 1st UP Forecast | 2.77 |
| 1st DOWN Forecast | -2.59 |
| 2nd DOWN Forecast | -4.46 |
| 3rd DOWN Forecast | -6.34 |
| 4th DOWN Forecast | -9.37 |
Clovis Oncology Inc ( NASDAQ USA Symbol : CLVS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CLVS Business Profile
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. It also provides lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. The company distributes its products primarily through specialty pharmacies and distributors to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, and Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. The company was incorporated in 2009 and is headquartered in Boulder, Colorado. Address: 5500 Flatiron Parkway, Boulder, CO, United States, 80301
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service